Nortriptyline Compared to Amitriptyline for the Treatment of Persistent Masticatory Myofascial Pain

Aims: To evaluate and compare the pharmacotherapeutic efficacies of two tricyclic antidepressant (TCA) drugs for masticatory myofascial pain (MFP): nortriptyline (NOR) and amitriptyline (AMI). Methods: Fifty patients with chronic MFP were included in the study; 30 were medicated with AMI only, and 20 took NOR after discontinuing AMI due to adverse effects. Pain diaries recording verbal pain scores (VPS) were utilized to compare posttreatment scores to baseline scores. Chi-square and t tests were used to analyze the data. Results: Across both groups, the mean ± standard deviation VPS score at the end of treatment (2.92 ± 3.2) was significantly lower compared to baseline (6.4 ± 1.75; P < .0001) and was a clinically meaningful (≥ 50%) difference. Initial VPS scores were similar in the AMI and NOR groups (6.27 ± 1.92 and 6.78 ± 1.98). At the end of the study, NOR patients reported a lower final VPS compared to AMI patients (2.83 ± 3.06 vs 4.55 ± 2.92; P = .039). The 50% improvement rate with NOR treatment was better than with AMI treatment (P = .036). The same maximal dosages were used by the patients who achieved a ≥ 50% success rate (20.96 ± 5.036 mg) than those who did not (21.667 ± 5.036 mg). Conclusion: TCAs are effective in reducing pain in patients with chronic MFP. NOR seems more effective and better tolerated than AMI, but due to study limitations, more data are needed to confirm these results.

amitriptyline;myalgia;myofascial pain;orofacial pain

1.Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD Pain: The effect on health related quality of life and the influence of pain duration. Health Qual Life Outcomes 2010;8:46.

2.Maixner W, Diatchenko L, Dubner R, et al. Orofacial pain prospective evaluation and risk assessment study—The OPPERA study. J Pain 2011;12(suppl):T4–T11.e1–e2.

3.Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for clinical and research applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral Facial Pain Headache 2014;28:6–27.

4.Kino K, Sugisaki M, Haketa T, et al. The comparison between pains, difficulties in function, and associating factors of patients in subtypes of temporomandibular disorders. J Oral Rehabil 2005;32:315–325.

5.Benoliel R, Eliav E, Sharav Y. Classification of chronic orofacial pain: Applicability of chronic headache criteria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:729–737.

6.Romero-Reyes M, Uyanik JM. Orofacial pain management: Current perspectives. J Pain Res 2014;7:99–115.

7.Shaffer SM, Brismée JM, Sizer PS, Courtney CA. Temporomandibular disorders. Part 2: Conservative management.J Man Manip Ther 2014;22:13–23.

8.Randolph CS, Greene CS, Moretti R, Forbes D, Perry HT. Conservative management of temporomandibular disorders: A posttreatment comparison between patients from a university clinic and from private practice. Am J Orthod Dentofacial Orthop 1990;98:77–82.

9.Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. Am Fam Physician 2015;91:378–386.

10.Truelove E, Huggins KH, Mancl L, Dworkin SF. The efficacy of traditional, low-cost and nonsplint therapies for temporomandibular disorder: A randomized controlled trial. J Am Dent Assoc 2006;137:1099–1107.

11.Fricton J, Look JO, Wright E, et al. Systematic review and meta-analysis of randomized controlled trials evaluating intraoral orthopedic appliances for temporomandibular disorders.J Orofac Pain 2010;24:237-254.

12.Rammelsberg P, LeResche L, Dworkin S, Mancl L. Longitudinal outcome of temporomandibular disorders: A 5-year epidemiologic study of muscle disorders defined by Research Diagnostic Criteria for Temporomandibular Disorders. J Orofac Pain 2003;17:9–20.

13.Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987;31:199–209.

14.Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil 2000;27:834–841.

15.Benoliel R, Eliav E, Elishoov H, Sharav Y. Diagnosis and treatment of persistent pain after trauma to the head and neck.J Oral Maxillofac Surg 1994;52:1138–1147.

16.Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: An open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. J Oral Facial Pain Headache 2015;29:144–151.

17.Preskorn SH. Introduction. Pharmacokinetics of psychotropic agents: Why and how they are relevant to treatment. J Clin Psychiatry 1993;54(suppl):S3–S7.

18.Gray AM, Pache DM, Sewell RD. Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol 1999; 378:161–168.

19.Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999;273:85–88.

20.Hamon M, Gozlan H, Bourgoin S, et al. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 1987;26:531–539.

21.Sacerdote P, Brini A, Mantegazza P, Panerai AE. A role for serotonin and beta-endorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol Biochem Behav 1987; 26:153–158.

22.Cai Z, McCaslin PP. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol 1992;219:53–57.

23.Ogata N, Yoshii M, Narahashi T. Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res 1989;476:140–144.

24.McCarson KE, Duric V, Reisman SA, Winter M, Enna SJ. GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. Brain Res 2006;1068:109–117.

25.Nakashita M, Sasaki K, Sakai N, Saito N. Effects of tricyclic and tetracyclic antidepressants on the three subtypes of GABA transporter. Neurosci Res 1997;29:87–91.

26.Ferjan I, Erjavec F. Characteristics of the inhibitory effect of tricyclic antidepressants on histamine release from rat peritoneal mast cells. Inflamm Res 1996;45(suppl):S17–S18.

27.Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000;20:603–610.

28.Veldhuijzen DS, Kenemans JL, van Wijck AJ, Olivier B, Kalkman CJ, Volkerts ER. Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: Preliminary findings. Psychopharmacology (Berl) 2006;183:462–470.

29.Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005;25:1048–1053.

30.Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study. Arch Intern Med 2003;163:59–64.

31.Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234–241.

32.Brunton LL, Chabner B, Goodman LS, Knollman B. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, ed 12. New York: McGraw-Hill Education, 2011.

33.Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85 (suppl):S3–S14.

34.Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology 1998;51:1166–1171.

35.Hyttel J, Christensen AV, Fjalland B. Neuropharmacological properties of amitriptyline, nortriptyline and their metabolites. Acta Pharmacol Toxicol (Copenh) 1980;47:53–57.

36.Haviv Y, Zadik Y, Sharav Y, Benoliel R. Painful traumatic trigeminal neuropathy: An open study on the pharmacotherapeutic response to stepped treatment. J Oral Facial Pain Headache 2014;28:52–60.

37.Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6: 301–355.

38.Botelho LM, Morales-Quezada L, Rozisky JR, et al. A framework for understanding the relationship between descending pain modulation, motor corticospinal, and neuroplasticity regulation systems in chronic myofascial pain. Front Hum Neurosci 2016;10:308.

39.Benoliel R, Birman N, Eliav E, Sharav Y. The International Classification of Headache Disorders: Accurate diagnosis of orofacial pain? Cephalalgia 2008;28:752–762.

40.Rhodus NL, Fricton J, Carlson P, Messner R. Oral symptoms associated with fibromyalgia syndrome. J Rheumatol 2003; 30:1841–1845.

41.Magnusson T, Egermark I, Carlsson GE. A longitudinal epidemiologic study of signs and symptoms of temporomandibular disorders from 15 to 35 years of age. J Orofac Pain 2000; 14:310–319.

42.Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet 2009;374:1252–1261.

43.Rose JT, Leahy MR, Martin IC, Westhead TT. A comparison of nortriptyline and amitriptyline in depression. Br J Psychiatry 1965;111:1101–1103.

44.Mendels J. Comparative trial of nortriptyline and amitriptyline in 100 depressed patients. Am J Psychiatry 1968; 124(suppl):S59–S62.

45.Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: A systematic review. BMC Anesthesiol 2016;16:12.

46.Ulrich S, Northoff G, Wurthmann C, et al. Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: A therapeutic window relationship. Pharmacopsychiatry 2001;34:33–40.